Literature DB >> 2449279

Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies.

J F O'Connor1, J P Schlatterer, S Birken, A Krichevsky, E G Armstrong, D McMahon, R E Canfield.   

Abstract

A variety of malignancies have been associated with the presence of human chorionic gonadotropin, hCG, its subunits, and fragments of its beta-subunit in blood and urine. The usefulness of these hCG-related tumor markers in nontrophoblastic malignancies has been inhibited by inadequate assay techniques. In order to achieve the required sensitivity and specificity, concentration steps and other procedures to remove cross-reacting human luteinizing hormone were necessary. In addition, the coexistence of a fragment of the hCG-beta or beta human luteinizing hormone subunit contributes to significant errors of measurement in urine. The importance of the hCG-beta fragment as a potential tumor marker has been recognized previously but no method was available to measure this antigen readily. We report here the development of a series of radioimmunometric, two-site assays which will accurately measure hCG, hCG-beta subunit, and the beta-subunit fragment directly in small volumes of unprocessed urine. These assays are highly specific, extremely sensitive, and not labor intensive since they employ microtiter plate procedures. Application of these assays to urine samples from patients with gynecological malignancies indicated that over 50% of all patients tested excreted the hCG-beta fragment in their urine. Also, this fragment comprised more than 50% of the moles of hCG immunoreactive components present in the specimens that were positive for hCG. This cancer marker is also demonstrable in trophoblastic malignant states such as choriocarcinoma in which the low molecular weight fragment can also be visualized directly by immunoblotting procedures. We conclude that a search for hCG immunoreactivity in the urine of patients with malignancies will be improved by the inclusion of accurate measurements of the prominent quantities of the beta fragment excreted by these individuals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449279

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG.

Authors:  S Birken; A Krichevsky; J O'Connor; J Schlatterer; L Cole; A Kardana; R Canfield
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

2.  HLH beta core fragment immunoreactivity in the urine of ovulating women: a sensitive and specific immunometric assay for its detection.

Authors:  G Kovalevskaya; S Birken; J O'Connor; J Schlatterer; Y Maydelman; R Canfield
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

3.  Preconception serum 1,1,1-trichloro-2,2,bis(p-chlorophenyl)ethane and B-vitamin status: independent and joint effects on women's reproductive outcomes.

Authors:  Fengxiu Ouyang; Matthew P Longnecker; Scott A Venners; Sara Johnson; Susan Korrick; Jun Zhang; Xiping Xu; Parul Christian; Mei-Cheng Wang; Xiaobin Wang
Journal:  Am J Clin Nutr       Date:  2014-10-22       Impact factor: 7.045

4.  Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance.

Authors:  Lisa S Kelly; Steven Birken; David Puett
Journal:  Mol Cell Endocrinol       Date:  2006-11-01       Impact factor: 4.102

5.  Total urinary follicle stimulating hormone as a biomarker for detection of early pregnancy and periimplantation spontaneous abortion.

Authors:  Q Qiu; J W Overstreet; H Todd; S T Nakajima; D R Stewart; B L Lasley
Journal:  Environ Health Perspect       Date:  1997-08       Impact factor: 9.031

6.  Abnormal biantennary sugar chains are expressed in human chorionic gonadotropin produced in the choriocarcinoma cell line, JEG-3.

Authors:  Shinji Takamatsu; Toshiyuki Katsumata; Noboru Inoue; Toshinori Watanabe; Yasuhisa Fujibayashi; Makoto Takeuchi
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 7.  Gonadotropins in doping: pharmacological basis and detection of illicit use.

Authors:  U-H Stenman; K Hotakainen; H Alfthan
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

8.  The role of human chorionic gonadotropin beta subunit elevation in small-cell lung cancer patients.

Authors:  M Szturmowicz; E Wiatr; A Sakowicz; J Slodkowska; K Roszkowski; S Filipecki; E R Rowinska-Zakrzewska
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.

Authors:  L A Cole; J H Nam
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

10.  Effect of environmental tobacco smoke on levels of urinary hormone markers.

Authors:  Changzhong Chen; Xiaobin Wang; Lihua Wang; Fan Yang; Genfu Tang; Houxun Xing; Louise Ryan; Bill Lasley; James W Overstreet; Joseph B Stanford; Xiping Xu
Journal:  Environ Health Perspect       Date:  2005-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.